Zyflo - Zileuton

Zyflo (Zileuton). Critical Therapeutics Inc. US Prescribing information, November 2005. 

Leukotriene receptor antagonists include montelukast sodium (Sngulair) and zafirlukast (Accolate). Zileuton (Zyflo) is classified as a leukotriene formation inhibitor. Additional information concerning these drags is found in the Summary Drag Table Antiasthma Drugs. 

Zileuton (Zyflo) is an inhibitor of leukotriene synthesis. The dose of zileuton tablets is 600 mg four times daily with meals and at bedtime. The recommended dose of zileuton extended-release tablets is two 600-mg tablets twice daily, within 1 hour after morning and evening meals (total daily dose 2,400 mg). 

Unoprostone (Rescula) Ophthalmic solution 0.15% Zafirleukast (Accolate) Oral 10, 20 mg tablets Zileuton (Zyflo))... 

Leukotriene inhibitors, one leukotriene inhibitor blocks leukotriene synthesis by inhibiting the action of 5-lipooxygenase (Zileuton Zyflo). Another blocks leukotriene receptors on the surface of smooth-muscle cells and eosinophils (Montelukast Singulair). 

New asthma drugs act by blocking the synthesis of leukotriene C4 from arachidonic acid. For example, zileuton (trade name Zyflo) inhibits the enzyme (called a lipoxygenase) needed for the first step of this process. By blocking the synthesis of leukotriene C4, a compound responsible for the disease, zileuton treats the cause of asthma, not just its symptoms. 

Generic name zileuton Trade name Zyflo anti-asthma drug... 

Zafirlukast (accolate) and montelukast (singulair) are leukotriene receptor antagonists. Zileuton (ZYFLO) is an inhibitor of 5-lipoxygenase, which catalyzes the formation of leukotiienes from arachidonic acid. 

Leukotriene (LK) modifiers include Zafirlukast (Accolate), zileuton (Zyflo) and nontelukast sodium (Singulair). 

The importance of thiophenes in medicinal chemistry can be highlighted by the enormous economic success of thiophene-containing drugs. Pharmaceuticals containing thiophenes such as duloxetine (Cymbalta), olanzapine (Zyprexa), tiotropium (Spiriva), raloxifene (Evista), and zileuton (Zyflo) had combined sales of more than 6 billion in the U.S. in 2010, while the blockbuster drug clopidogrel (Plavix) alone obtained sales in excess of 6 billion in the same year. 

---